Impact of donor-specific antibodies on long-term graft survival with pediatric liver transplantation

Figure 1 Allele distribution. A: Distribution of human leucocyte antigen (HLA) antibodies; B: Distribution of donor-specific antibodies (DSAs) within group 1; C: Top 15 DSA alleles. Vertical axis: numbers, quantitative; horizontal axis: categories of anti-HLA antibodies and subcategories of DSAs; columns: DSA-positive patients shown in green, DSA-negative patients shown in light grey. HLA: Human leucocyte antigen; DSA: Donor-specific antibody.

Figure 2 Donor-specific antibody presences on graft survival. Kaplan-Meyer survival plot; vertical axis: Graft survival (decimal); horizontal axis: Time of graft survival (months); graphs: Donor-specific antibody (DSA)-negative patients are shown in dark grey, numbers at risk n = 34; DSA-positive patients are shown in green, numbers at risk n = 38. DSA: Donor-specific antibody.

Figure 3 Number of donor-specific antibodies on graft survival. Kaplan-Meyer survival plot; vertical axis: Graft survival (decimal); horizontal axis: Time of graft survival (months); graphs: Patients with single donor-specific antibody (DSA) are shown in a dark grey, numbers at risk n = 19; patients with multiple DSAs are shown in green, numbers at risk n = 19. DSA: Donor-specific antibody.

Figure 4 Mean fluorescence intensity levels on graft survival. Kaplan-Meyer survival plot; vertical axis: Graft survival (decimal); horizontal axis: Duration of graft survival (months); graphs: Patients who have donor-specific antibodies (DSAs) with mean fluorescence intensity (MFI) above 1500 are shown in dark grey; numbers at risk n = 22; patients who have DSAs with MFI above 10000 are shown in green; numbers at risk n = 16. MFI: Mean fluorescence intensity.